FDA Logo links to FDA home pageCenter for Devices and Radiological Health, U.S. Food and Drug AdministrationHHS Logo links to Department of Health and Human Services website

FDA Home Page | CDRH Home Page | Search | CDRH A-Z Index | Contact CDRH U.S. Food and Drug Administration Center for Devices and Radiological Health [Skip navigation]
horizonal rule

Super Search
510(k) | Registration & Listing | Adverse Events | PMA | Classification | CLIA
CFR Title 21 | Advisory Committees | Assembler | Recalls | Guidance | Standards
 

 

Adverse Event Report

DATASCOPE CORP./COLLAGEN PRODUCTS VASOSEAL ES EXTRAVASCULAR SECURITY DEVICE   back to search results
Catalog Number 76000
Event Date 09/07/2001
Event Type  Injury   Patient Outcome  Required Intervention;
Event Description

The customer reported that following a ptca procedure in 2001, a vasoseal es was deployed. A small hematoma was noted post deployment. After returning to the icu, the pt experienced a vasovagal episode and was intermittently unstable. On the same day, a cat scan revealed a right retroperitoneal bleed and a possible pseudoaneurysm in the right femoral artery. On the next day, a sonogram of the bilateral lower extremity revealed deep vein thrombosis of the right femoral artery at the groin, a pseudoaneurysm, and a large amount of retroperitoneal hematoma. The physician reported that approx 36 hours post deployment, the pt was taken to the operating room and was hemodynamically stabilized. No further complications have been reported.

 
Manufacturer Narrative

Based on the co's experience, hematomas and pseudoaneurysms can result if the vasoseal collagen is not placed accurately over the arterial puncture site or if it is displaced following the procedure. Retroperitoneal bleeds can result if the initial puncture site is higher than that recommended for use with vasoseal or if a double wall stick occurs. The vasoseal instructions for use states that in order to optimize placement of the vasoseal collagen, the following points should be observed when performing the arterial puncture: the puncture of the common femoral artery should be made 3-4 cm below the inguinal ligament to allow compression of the artery and placement of the sheath without kinking. A single puncture to the anterior, medial aspect of the common femoral artery is recommended. Puncture of the superficial femoral artery should be avoided. In addition, the skin and artery should be punctured at a 45-60 degree angle to allow for placement of catheters and to promote proper placement of the vasoseal collagen in the artery. Based on the co's commercial experience, the frequency of reported hematomas, pseudoaneurysms, and retroperitoneal bleeds is extremely low. Based on the co's experience these complications do not indicate that the device is defective. The risk of hematoma, pseudoaneursym, and retroperitoneal bleed are all recognized as potential complications associated with cardiac catheterization procedures.

 
Search Alerts/Recalls

  new search  |  submit an adverse event report

Brand NameVASOSEAL ES
Type of DeviceEXTRAVASCULAR SECURITY DEVICE
Baseline Brand NameVASOSEAL ES
Baseline Generic NameEXTRAVASCULAR SECURITY DEVICE
Baseline Catalogue Number76000
Baseline Device FamilyVASO 2
Baseline Device 510(K) Number
Baseline Device PMA NumberP920004
Baseline Shelf Life Information
Baseline Preamendment? No
Transitional? No
510(K) Exempt? No
Shelf Life(Months)24
Date First Marketed01/22/1999
Manufacturer (Section F)
DATASCOPE CORP./COLLAGEN PRODUCTS
1300 macarthur blvd.
mahwah NJ 07430
Manufacturer (Section D)
DATASCOPE CORP./COLLAGEN PRODUCTS
1300 macarthur blvd.
mahwah NJ 07430
Manufacturer Contact
laurie bonilla
1300 macarthur blvd.
mahwah , NJ 07430
(201) 995 -8775
Device Event Key343449
MDR Report Key354229
Event Key333735
Report Number9681824-2001-00114
Device Sequence Number1
Product CodeMGB
Report Source Manufacturer
Source Type Company Representative
Reporter Occupation Other
Type of Report Initial
Report Date 09/10/2001
1 Device Was Involved in the Event
1 Patient Was Involved in the Event
Date FDA Received10/03/2001
Is This An Adverse Event Report? Yes
Is This A Product Problem Report? No
Device Operator Health Professional
Device Catalogue Number76000
Was Device Available For Evaluation? No
Is The Reporter A Health Professional? Yes
Was the Report Sent to FDA? No
Distributor Facility Aware Date09/10/2001
Device Ageunknown
Event Location Hospital
Date Manufacturer Received09/10/2001
Was Device Evaluated By Manufacturer? Device Not Returned To Manufacturer
Is The Device Single Use? Yes
Is the Device an Implant? No
Is this an Explanted Device?
Type of Device Usage Initial

Patient TREATMENT DATA
Date Received: 10/03/2001 Patient Sequence Number: 1
#TreatmentTreatment Date
1,ASA, 4000 UNITS HEPARIN, AGGRASTAT GTT 7 ML/HR.,,
2,275 MG PLAVIX.,

Database last updated on January 06, 2009

horizonal rule

CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page

Center for Devices and Radiological Health / CDRH